Graft-versus-Leukemia Effect and Its Clinical Implications

References

• Bortin M. M., Rimm A. A., Saltzstein E. C. Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia. Science 1973; 179: 811–813
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Rimm A. A., Saltzstein E. C., Rodey G. E. Graft versus leukemia. III. Apparent independent antihost and antileukemic activity of transplanted immunocompetent cells. Transplantation 1973; 16: 182–188
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Rimm A. A., Rose W. C., Saltzstein B. C. Graft versus leukemia. V. Absence of antileukemic effect using allogeneic H-2-identical immunocompetent cells. Transplantation 1974; 18: 280–283
   PubMed Web of Science ®Google Scholar
• Chester S. J., Esparza A. R., Albala M. M. Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy. Cancer Res. 1975; 35: 634–636
   PubMed Web of Science ®Google Scholar
• Chester S. J., Esparza A. R., Flinton L. J., Simon J. D., Kelley R. J., Albala M. M. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice. Cancer Res. 1977; 37: 3494–3496
   PubMed Web of Science ®Google Scholar
• Barness D. W. H., Corp M. J., Neal F. E. Treatment of murine leukemia with X rays and homologous bone marrow. Brit. Med. J. 1956; ii: 626–627
   Google Scholar
• Barness D. W., Loutit J. F. Treatment of murine leukemia with X-rays and homologous bone marrow. II. Brit. J. Haematol. 1957; 3: 241–252
   PubMed Web of Science ®Google Scholar
• De Vries M. J., Vos O. Treatment of mouse lymphosarcoma by total-body X irradiation and by injection of bone marrow and lymph node cells. J. Natl. Cancer Inst. 1958; 21: 1117–1129
   PubMed Web of Science ®Google Scholar
• Woodruff M. F. A., Sywes M. O., Anderson N. F. The effect of intraperitoneal injection of thoracic duct lymphocytes from normal and immunized rats in mice inoculated with the Landschutz ascites tumour. Brit. J. Cancer 1963; 17: 482–487
   PubMed Web of Science ®Google Scholar
• Woodruff M. F. A., Symes M. O., Stuart A. E. The effect of rats spleen cells on two transplanted mouse tumours. Brit. J. Cancer 1963; 17: 320–327
   PubMed Web of Science ®Google Scholar
• Wallis V., Davies A. J. S., Koller P. C. Inhibition of radiation-induced leukemia by the injection of haematopoietic tissue: A study of chimerism. Nature 1966; 210: 500–504
   PubMed Web of Science ®Google Scholar
• Alexander P., Connell D. I., Mikulska Z. B. Treatment of a murine leukemia with spleen cells or sera from allogeneic mice immunized against the tumor. Cancer Res. 1966; 26: 1508–1515
   PubMed Web of Science ®Google Scholar
• Boranic M. Transient graft-versus-host reaction in the treatment of leukemia in mice. J. Natl. Cancer Inst. 1968; 41: 421–437
   PubMed Web of Science ®Google Scholar
• Boranic M., Tonkovic I. Time pattern of the antileukemic effect of graft-versus-host reaction in mice. Cancer Res. 1971; 31: 1140–1147
   PubMed Web of Science ®Google Scholar
• MathÉ G., Amiel J. L., Schwarzenberg L., Cattan A., Schneider M. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res. 1965; 25: 1525–1531
   PubMed Web of Science ®Google Scholar
• Odom L. F., August C. S., Githens J. H., Humbert J. R., Morse H., Peaman D., Sharma B., Rusnak S. L., Johnson F. B. Remission of relapsed leukemia during graft-versus-host reaction. A “graft-versus-leukemia reaction” in man?. Lancet 1978; 2: 537–540
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. New Engl. J. Med. 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. New Engl. J. Med. 1981; 304: 1529–1532
   PubMed Web of Science ®Google Scholar
• Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 1978; 148: 1687–1698
   PubMed Web of Science ®Google Scholar
• Mason D. W. Subsets of T cells in the rat mediating lethal graft-versus-host disease. Transplantation 1981; 32: 222–226
   PubMed Web of Science ®Google Scholar
• Vallera D. A., Solderling C. C. B., Kersey J. H. Bone marrow transplantation accros major histocompatibility barriers in mice: Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J. Immunol. 1982; 128: 871–875
   PubMed Web of Science ®Google Scholar
• Kernan N., Collins N. H., Juliano L., Cartagena L., Dupont B., O'Reilly R. J. Clonable T lumphocytes in T cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770–773
   PubMed Web of Science ®Google Scholar
• Horowitz M. H., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H-J., Rimm A. A., Ringden O., Rozman C., Speck B., Truitt R. L., Zwaan F. E., Bortin M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Roy C., Ghayur T., Kongshavn P. A. L., Lapp W. S. Natural killer activity by spleen, lymphnode and thymus cells during the graft versus host reaction. Transplantation 1982; 34: 144–146
   PubMed Web of Science ®Google Scholar
• Charley M. R., Milhael A., Bennet M., Gillian J. N., Sontheimer R. D. Prevention of lethal minor-determinate graft versus-host disease in mice by the in vivo administration of anti-asialo GM1. J. Immunol. 1983; 131: 2101–2103
   PubMed Web of Science ®Google Scholar
• Ghayur T., Seemayer T. A., Kongshavn P. A. L., Gartner J. G., Lapp W. S. Graft-versus-host reactions in the beige mouse. An investigation of the role of host and donor natural killer cells in the pathogenesis of graft-versus-host disease. Transplantation 1987; 44: 261–267
   PubMed Web of Science ®Google Scholar
• Varkila K. Depletion of asialo GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific T cells. Clin. Exp. Immunol. 1987; 69: 652–659
   PubMed Web of Science ®Google Scholar
• Ghayur T., Seemayer T. A., Lapp W. S. Prevention of murine graft-versus-host disease by inducing and eliminating ASGM1 cells of donor origin. Transplantation 1988; 45: 586–590
   PubMed Web of Science ®Google Scholar
• Ferrara J. L. M., Guillen F. J., Van Dijken P. J., Marion A., Murphy G. F., Burakoff S. J. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989; 47: 50–54
   PubMed Web of Science ®Google Scholar
• Johnson B. D., Truitt R. A decrease in graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation 1992; 54: 104–112
   PubMed Web of Science ®Google Scholar
• Macdonald G. C., Gartner J. G. Prevention of acute lethal graft-versus-host disease in F1 hybrid mice by pretreatment of the graft with anti-NK1.1 and complement. Transplantation 1992; 54: 147–151
   PubMed Web of Science ®Google Scholar
• Lapp W. E., Ghayur T., Mendes M., Seddik M. The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol. Rev. 1985; 66: 107–134
   Web of Science ®Google Scholar
• Xun C., Brown S. A., Jennings C. D., Henslee-Downey P. J., Thompson J. S. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Transplantation 1993; 56: 409–417
   PubMed Web of Science ®Google Scholar
• Xun C. R., Thompson J. S., Jennings C. D., Brown S. A. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Transplantation 1995; 60: 821–827
   PubMed Web of Science ®Google Scholar
• Hoffmann T., Theobald M., Bunjes D., Weiss M., Heimpel H., Heit W. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant. 1993; 12: 1–8
   PubMed Web of Science ®Google Scholar
• Datta A. R., Barrett A. J., Jiang Y. Z., Guimaraes A., Marvroudis D. A., Van Rhee F., Gordon A. A., Madrigal A. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 1994; 14: 517–524
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Duncombe A. S., Reittie J. E., Bello-Fernandes C., Gottlieb D. J., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. Interleukin 2 infusion induces haematopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Brit. J. Haematol. 1991; 77: 237–244
   PubMed Web of Science ®Google Scholar
• Higuchi C. M., Thompson J. A., Petersen F. B., Buchner C. D., Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Massumoto C., York A., Higuchi C. M., Buckner C. D., Thompson J. A., Petersen F. B., Fefer A. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1993; 12: 159–163
   PubMed Web of Science ®Google Scholar
• Benyunes M. C., Higuchi C., York A., Lindgren C., Thompson J. A., Buckner C. D., Fefer A. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. 1995; 16: 283–288
   PubMed Web of Science ®Google Scholar
• Hashino S., Imamura M., Kobayashi S., Kobayashi H., Fujii Y., Kobayashi M., Hirano S., Minagawa T., Kasai M., Sakurada K., Miyazaki T. Systemic administration of IL-2 after autologous bone marrow transplantation. Therapeutic Plasmapheresis 1993; 12: 383–387
   Google Scholar
• Hashino S., Imamura M., Kobayashi S., Kobayashi H., Tanaka J., Kasai M., Miyazaki T. Interleukin-2 therapy immediately after autologous marrow transplantation using cryopreserved marrow for a patient with acute promyelocytic leukemia. Low Temp. Med. 1993; 19: 36–41
   Google Scholar
• Tratkiewicz J. A., Szer J. Loss of natural killer activity as an indicator of relapse in acute leukemia. Clin. Exp. Immunol. 1990; 80: 241–246
   PubMed Web of Science ®Google Scholar
• Adler A., Cherknick P., Whiteside T. L., Lotzova E., Herberman R. B. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: 1. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Verfaillie C., Kay N., Miller W., McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990; 76: 401–408
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drezler H. G., Hazlehurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Murray C., Gonin R., Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964–971
   PubMed Web of Science ®Google Scholar
• Cohen P., Vourka-Karussis U., Weiss L., Slavin S. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor-and host-specific alloantigens. J. Immunol. 1993; 151: 4803–4810
   PubMed Web of Science ®Google Scholar
• KÄRre K., Ljunggren H. G., Piontek G., Kiessling R. Selective recognition of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675–678
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989; 49: 187–376
   Google Scholar
• Karlhofer F. M., Ribaudo R., Yokoyama W. M. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 1992; 358: 66–70
   PubMed Web of Science ®Google Scholar
• Gumperz J. E., Parham P. The enigma of the natural killer cell. Nature 1995; 378: 245–248
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation—Amplification of natural host defence mechanisms agianst cancer by recombinant IL-2. Nat. Immun. Cell Growth Regul. 1988; 7: 180–184
   PubMedGoogle Scholar
• Ackerstein A., Kedar E., Slavin S. Use of recombinant human interleukin-2 in cinjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991; 78: 1212–1215
   PubMed Web of Science ®Google Scholar
• Charak B. S., Brynes R. K., Grosken S., Chen S-C., Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187–2190
   PubMed Web of Science ®Google Scholar
• Charak B. S., Bryson R. K., Katsuda S., Groshen S., Chen S-C., Mazumder A. Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of interleukin 2 therapy. Cancer Res. 1991; 51: 2015–2020
   PubMed Web of Science ®Google Scholar
• Charak B. S., Agah R., Mazumder A. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 1992; 80: 179–184
   PubMed Web of Science ®Google Scholar
• Charak B. S., Bryson R. K., Chogyoji M., Kortes V., Tefti M., Mazumder A. Graft versus leukemia effect after transplantation with interleukin-2-activated bone marrow. Transplantation 1993; 56: 31–37
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Nagler A., Naparstek E., Weiss L. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation. Blood 1990; 76, (suppl. 1), 566a
   Google Scholar
• Slavin S., Or R., Naparstek E., Kapelushnik Y., Weiss L., Ackerstein A., Vourka-Karussis U., Nagler A. Eradication of minimal residual disease (MRD) following autologous (ABMT) and allogeneic bone marrow transplantation (BMT) by cytokine-mediated immunotherapy (CM1) and cell-mediated cytokine-activated immunotherapy (CCI) in experimental animals and man. Blood 1992; 80, (suppl. 1), 535a
   Google Scholar
• Weiss L., Reich S., Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: 1. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest. 1992; 10: 19–26
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Sachs D. H. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. USA 1990; 87: 5633–5637
   PubMed Web of Science ®Google Scholar
• Sykes M., Abraham V. S., Harty M. W., Pearson D. A. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 1993; 150: 197–205
   PubMed Web of Science ®Google Scholar
• Sykes M., Harty M. W., Szot G. L., Pearson D. A. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560–2569
   PubMed Web of Science ®Google Scholar
• Zeis M., Uharek L., Glass B., Gaska T., Gassmann W., Mueller-Ruchholtz W. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplantation 1994; 14: 711–715
   PubMed Web of Science ®Google Scholar
• Vourka-Karussis U., Karussis D., Ackerstein A., Slavin S. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp. Hematol. 1995; 23: 196–201
   PubMed Web of Science ®Google Scholar
• Hashino S., Imamura M., Zhu X., Imai K., Kobayashi S., Tanaka J., Fujii Y., Kasai M., Miyazaki T. Effects of interleukin 2 on leukemia development after bone marrow transplantation in AKR/J mice. Transplantation 1995; 59: 1642–1645
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Hoyles K. A., Sachs D. H. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J. Exp. Med. 1990; 171: 645–658
   PubMed Web of Science ®Google Scholar
• Abraham V. S., Sachs D. H., Sykes M. Mechanism of protection from GVHD mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population. J. Immunol. 1990; 148: 3746–3752
   Web of Science ®Google Scholar
• Sykes M., Pearson D. A., Szot G. L. IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25 h period beginning on the day following bone marrow transplantation. Bone Marrow Transplantation 1995; 15: 395–399
   PubMed Web of Science ®Google Scholar
• Tanaka J., Imamura M., Zhu X., Kobayashi S., Imai K., Hashino S., Sakurada K., Kasai M., Higa T. Potential benefit of rhG-CSF mobilized peripheral blood stem cells for allogeneic transplantation. Blood 1994; 3595–3596
   PubMed Web of Science ®Google Scholar
• Bensinger W. I., Weaver C. H., Appelbaum F. R., Rowley S., Demier T., Sanders J., Storb R., Buchner C. D. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655–1658
   PubMed Web of Science ®Google Scholar
• Korbling M., Przepiorka D., Huh Y. O., Engel H., Van Besien K., Giralt S., Anderson B., Kleine H. D., Seong D., Deisseroth A. B., Andreeff M., Champlin R. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1655
   PubMed Web of Science ®Google Scholar
• Schmitz N., Dreger P., Suttorp M., Rohwedder E. B., Haferlach T., Loffler H., Hunter A., Russell N. H. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666–1672
   PubMed Web of Science ®Google Scholar
• Kedar E., Tsuberi B. Z., Landesberg A., Anafi M., Leshem B., Gillis S., Urdal D. L., Slavin S. In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation. Bone Marrow Transplant. 1988; 3: 297–314
   PubMed Web of Science ®Google Scholar
• Bieder A., Weiss L., Slavin S. The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice. Bone Marrow Transplant. 1992; 9: 421–426
   PubMed Web of Science ®Google Scholar
• Charak B. S., Brown E. Z., Mazumder A. Augmentation of murine hematopoiesis by interleukin 2-activated irradiated T cells. Transplantation 1995; 60: 589–594
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wang M-G., Pearson D. A., Szot G. L., Sykes M. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 1994; 58: 1385–1393
   PubMed Web of Science ®Google Scholar
• Wang M.-G., Szebeni J., Pearson D. A., Szot G. L., Sykes M. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation 1995; 60: 481–490
   PubMed Web of Science ®Google Scholar
• Sykes M., Szot G. L., Nguyen P. L., Pearson D. A. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429–2438
   PubMed Web of Science ®Google Scholar
• Glazier A., Tutschka P. J., Farmer E. R., Santos G. W. Graft versus host disease in cyclosporine A-treated rats after syngeneic and autolgous bone marrow reconstitution. J. Exp. Med. 1983; 158: 1–8
   PubMed Web of Science ®Google Scholar
• Glazier A., Tutschka P. J., Farmer E. R. Studies on the immunobiology of syngeneic and autologous graft-versus-host disease in cyclosporine treated rats. Transplant. Proc. 1983; 15: 3035–3041
   PubMed Web of Science ®Google Scholar
• Sorokin R., Kimura H., Schroder K., Wilson D. H., Wilson D. B. Cyclosporine-induced autoimmunity: Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J. Exp. Med. 1986; 164: 1615–1625
   PubMed Web of Science ®Google Scholar
• Cheney R. J., Sprent J. Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T cell differentiation. Transplant. Proc. 1985; 17: 528–530
   Web of Science ®Google Scholar
• Beschorner W. E., Namnoum J. D., Hess A. D., Shinn C. A., Santos G. W. Cyclosporin A and the thymus: Immunopathology. Am. J. Pathol. 1987; 126: 487–496
   PubMed Web of Science ®Google Scholar
• Hess A. D., Horowitz L., Beschorner W. E., Santos G. W. Development of graft-versus-host disease-like syndrome in cyclosporine treated rats after syngeneic bone marrow transplantation: I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity including autoreactivity. J. Exp. Med. 1985; 161: 718–730
   PubMed Web of Science ®Google Scholar
• Urdahl K. B., Pardoll D. M., Jenkins M. K. Cyclosporin A inhibits positive selection and delays negative selection in αβTCR transgenic mice. J. Immunol. 1994; 152: 2853–2859
   PubMed Web of Science ®Google Scholar
• Hess A. D., Vogelsang G. B., Heyd J., Beschorner W. E. Cyclosporine induced syngeneic graft-versus-host disease: Assessment of T-cell differentiation. Transplant. Proc. 1987; 19: 2683–2686
   PubMed Web of Science ®Google Scholar
• Cohen D. J., Loerscher R., Rubin M., Tilney N. L., Carpenter C. B., Strom T. B. Cyclosporine: A new immunosuppressive agent for organ transplantation. Ann. Intern. Med. 1984; 101: 667–682
   PubMed Web of Science ®Google Scholar
• Jenkins M. K., Schwartz R. W., Pardoll D. M. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–1658
   PubMed Web of Science ®Google Scholar
• Shi Y., Sakai B. M., Green D. R. Cyclosporin A inhibits activation-induced cell death in T cell hybridomas and thymocytes. Nature 1989; 339: 625–627
   PubMed Web of Science ®Google Scholar
• Bryson J. S., Jennings C. D., Caywood B. E., Kaplan A. M. Thyl+ bone marrow cells regulate the induction of murine syngeneic graft-versus-host disease. Transplantation 1993; 56: 941–945
   PubMed Web of Science ®Google Scholar
• Bucy R. P., Xu X. Y., Huang G. Q. Cyclosporin A-induced autoimmune disease in mice. J. Immunol. 1993; 151: 1039–1050
   PubMed Web of Science ®Google Scholar
• Fischer A. C., Beschorner W. E., Hess A. D. Age related factors in the induction of syngeneic GVHD. Transplant. Proc. 1989; 21: 3033–3035
   PubMed Web of Science ®Google Scholar
• Beschorner W. E., Hess A. D., Shinn C. A., Santos G. W. Transfer of cyclosporine A associated syngeneic graft-versus-host disease (GVHD) by thymocytes: Resemblance to chronic GVHD. Transplantation 1988; 45: 209–215
   PubMed Web of Science ®Google Scholar
• Bos G. M. J., Majoor G. D., Van De Gaar M. J., Van Breda Vriesman P. J. C. T-helper lymphocytes and syngeneic graft-versus-host disease. Transplant. Proc. 1989; 21: 3016–3017
   PubMed Web of Science ®Google Scholar
• Beschorner W. E., Shinn C. A., Fischer A. C., Santos G. W., Hess A. D. Cyclosporine-induced pseudo-graft-versus-host disease in the early post-cyclosporine period. Transplantation 1988; 46, (suppl), 112–117
   Web of Science ®Google Scholar
• Hess A. D., Fischer A. C., Beschorner W. E. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets. J. Immunol. 1990; 145: 526–533
   PubMed Web of Science ®Google Scholar
• Fischer A. C., Beschorner W. E., Hess A. D. Requirements for the induction and adoptive transfer of syngeneic GVHD. J. Exp. Med. 1989; 169: 1031–1041
   PubMed Web of Science ®Google Scholar
• Fischer A. C., Laukis M. K., Horowitz L., Beschorner W. E., Hess A. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. J. Immunol. 1989; 143: 827–832
   PubMed Web of Science ®Google Scholar
• Hess A. D., Fischer A. C. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. Transplantation 1989; 48: 895–900
   PubMed Web of Science ®Google Scholar
• Fischer A. C., Ruvolo P. P., Bust R., Horowitz L. R., Bright E. C., Hess J. M., Beschorner W. E., Hess A. D. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. J. Immunol. 1995; 154: 3713–3725
   PubMed Web of Science ®Google Scholar
• Bryson J. S., Lake-Bullock H., Pelugh D. L., Jennings D., Stuart P. M., Caywood B. E., Kaplan A. M. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60: 171–178
   PubMed Web of Science ®Google Scholar
• Vogelsang G. B., Jones R. J., Hess A. D., Geller R., Schucter L., Santos G. W. Induction of autologous graft-versus-host disease. Transplant. Proc. 1989; 21: 2997–2998
   PubMed Web of Science ®Google Scholar
• Dale B. M., Atkinson K., Kotasek D., Biggs J. C., Sage R. E. Cyclosporine-induced graft-vs-host disease in two patients receiving syngeneic bone marrow transplants. Transplant. Proc. 1989; 21: 3816–3817
   PubMed Web of Science ®Google Scholar
• Jones R. J., Hess A. D., Mann R. B., Piantadosi S., Vogelsang G. B., Farmer E. R., Geller R. B., Santos G. W. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; i: 745–756
   Google Scholar
• Hashino S., Imamura M., Kobayashi S., Kobayashi H., Kasai M., Miyazaki T. Monoclonal gammopathy (IgA: λ) after autologous T-cell-depleted bone marrow transplantation in a patient with non-Hodgikin's lymphoma. Ann. Hematol. 1993; 67: 135–137
   PubMed Web of Science ®Google Scholar
• Kennedy M. J., Vogelsang G. B., Jones R. J., Farmer E. R., Hess A. D., Altomonte V., Huelskamp A. M., Davidson N. E. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 1994; 12: 249–257
   PubMed Web of Science ®Google Scholar
• Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiotics 1987; 40: 1249–1256
   PubMed Web of Science ®Google Scholar
• Hashino S., Imamura M., Tanaka J., Kasai M., Higa T., Asaka M. Antitumor effect in cyclosporin A- or FK506-treated mice after syngeneic bone marrow transplantation. Leuk. Lymphoma 1996, in press
   Web of Science ®Google Scholar
• Stalhandske T., Eriksoo E., Sandberg B-M. A novel quinoline-carboxamide with interesting immunomodulatory activity. Int. J. Immunopharmacol. 1982; 4: 336
   Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 1990; 144: 4472–4476
   PubMed Web of Science ®Google Scholar
• Larson E. Z., Joki A., Stalhandske T. Mechanisms of action of the immunomodulator LS2616 on T cell responses. Int. J. Immunopharmacol. 1987; 9: 425–431
   PubMed Web of Science ®Google Scholar
• Kalland T., Aim G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS2616 on growth and metastasis of the murine B16F10 melanoma. Cancer Res. 1986; 46: 3018–3022
   PubMed Web of Science ®Google Scholar
• Kalland T., Maksimova A., Stalhandske T. Prophylaxis and treatment of experimental tumors with immunomodulator LS2616. Int. J. Immunopharmacol. 1985; 7: 390–394
   Web of Science ®Google Scholar
• Bengtson M., Simonsson B., Carlsson K., Nilsson B., Smedmyr B., Termander B., Oberg G., Totterman T. H. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplantation 1992; 53: 882–888
   PubMed Web of Science ®Google Scholar
• Rowe J., Ryan D., Dipersio J., Gaspari A., Nilsson B., Larsson L., Liesveld J., Kouides P., Simonsson B. Autografting in chronic myelogenous leukemia followed by immunotherapy. Stem Cells 1993; 11, (suppl. 3), 34–42
   PubMed Web of Science ®Google Scholar
• Weiss L., Weigensberg M., Morecki S., Bar S., Cobbold S., Waldmann H., Slavin S. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol. Immunother. 1990; 31: 236–242
   PubMed Web of Science ®Google Scholar
• Okunewick J. P., Kochiban D. L., Machen L. L., Buffo M. J. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone Marrow Transplantation 1991; 8: 445–452
   PubMed Web of Science ®Google Scholar
• Aizawa S., Sado T. Graft-versus-leukemia effect in MHC-compatible and -incompatible alogeneic bone marrow transplantation of radiation-induced leukemia-bearing mice. Transplantation 1991; 52: 885–889
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplantation 1991; 8: 51–58
   PubMed Web of Science ®Google Scholar
• Hercend T. H., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Muray C., Bonhoun C., Ythier A., Ritz J. Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Harris D. T. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplantation 1995; 15: 17–23
   PubMed Web of Science ®Google Scholar
• Zeis M., Uharek L., Glass B., Gaska T., Gassmann W., Muller-Ruckholtz W. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts. Bone Marrow Transplantation 1994; 14: 711–715
   PubMed Web of Science ®Google Scholar
• Hauch M., Gazzola M. V., Small T., Bordignon C., Barrett L., Cunnungham I., Castro-Malaspinia H., O'Reilly R. J., Keever C. A. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250–2262
   PubMed Web of Science ®Google Scholar
• Zeis M., Uharek L., Glass B., Goska T., Steinmann J., Gassmann W., Loffler H., Muller-Ruchholtz W. Allogeneic NK cells as potent anti leukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995; 59: 1734–1736
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Gottlieb D. J., Bianchi A. C., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma-interferon and tumor necrosis factor by interleukin 2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Holler E., Kolb H. J., Moller A., Kempeni J., Liesenfeld S., Pechumer H., Lehmacher W., Ruckdeschel G., Gleixner B., Riedner C., Ledderose G., Brehm G., Mittelmuller J., Wilmanns W. Increased serum levels of tumor necrosis factor precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016
   PubMed Web of Science ®Google Scholar
• Robinet E., Ibrahim A., Truneh A., Ostronoff M., Mishal E., Zambon E., Gay F., Hayat M., Pico J-L., Chouaib S. Serum levels and receptor expression of tumor necrosis factor following human allogeneic and autologous bone marrow transplantation. Transplantation 1992; 53: 574–579
   PubMed Web of Science ®Google Scholar
• Shalaby M. R., Fendly B., Sheenan K. C., Schreiber R. D., Amman A. F. Prevention of the graft-versus-host reaction in new born mice by antibodies to tumor necrosis factor alpha. Transplantation 1989; 47: 1957–1061
   Web of Science ®Google Scholar
• Symington F. W., Pepe M. S., Chen A. B., Deliganis A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation 1990; 50: 518–521
   PubMed Web of Science ®Google Scholar
• Piguet P-F., Grau G. E., Allet B., Vassali P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J. Exp. Med. 1987; 166: 1280–1289
   PubMed Web of Science ®Google Scholar
• Tanaka J., Imamura M., Kasai M., Masauzi N., Watanabe M., Matsuura A., Morii K., Kiyama Y., Naohara T., Saito M., Higa T., Honke K., Gasa S., Sakurada K., Miyazaki T. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Br. J. Haematol. 1993; 85: 558–565
   PubMed Web of Science ®Google Scholar
• Imamura M., Hashino S., Kobayashi H., Kobayashi S., Hirano S., Minagawa T., Tanaka J., Fujii Y., Kobayashi M., Kasai M., Sakurada K., Miyazaki T. Serum cytokine levels in bone marrow transplantation: Synergistic interaction of interleukin-6, interferon-γ, and tumor necrosis factor-α in graft-versus-host disease. Bone Marrow Transplantation 1994; 13: 745–751
   PubMed Web of Science ®Google Scholar
• Mowat A. M. Antibodies to IFNγ prevent immunologically mediated intestinal damage in murine grfat-versus-host reaction. Immunology 1989; 68: 18–23
   PubMed Web of Science ®Google Scholar
• Niederweiser D., Herald M., Woloszczuk W., Aulitzky W., Meister B., Tilg H., Gastl G., Bowden R., Huber C. Endogenous IFN-gamma during human bone marrow transplantation: Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620–625
   PubMed Web of Science ®Google Scholar
• Wall D. A., Hamberg S. D., Reynolds D. S., Burakoff S. J., Abbas A. K., Ferrara J. L. M. Immunodeficiency in graft-versus-host disease. I. Mechanism for immune suppression. J. Immunol. 1988; 140: 2970–2976
   PubMed Web of Science ®Google Scholar
• Cleveland M. G., Annable C. R., Klimpel G. R. In vivo and in vitro production of IFN-β and IFN-γ during graft-vs-host disease. J. Immunol. 1988; 141: 3349–3356
   PubMed Web of Science ®Google Scholar
• Klimpel G. R., Annable C. R., Cleveland M. G., Jerrells T. R., Patterson J. C. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J. Immunol. 1990; 144: 84–93
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Naparstek E., Or R., Weiss L. The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD?. Bone Marrow Transplantation 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Shih C., Lefever A. V., Tempelis L. D., Andreani M., Bortin M. M. Characterization of alloimmunization induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vitro. J. Immunol. 1983; 131: 2050–2058
   PubMed Web of Science ®Google Scholar
• Kloosterman T. C., Tielemans M. J. C., Mastens A. C. M., Van Bekkum D. W., Hagenbeek A. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia. Bone Marrow Transplantation 1994; 14: 15–22
   PubMed Web of Science ®Google Scholar
• Van Lochem E., De Gast B., Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activation. Bone Marrow Transplantation 1992; 11: 181–183
   Google Scholar
• Westcott O., Dorsch S., Roser B. Adoptive immunotherapy in the rat without graft-versus-host complications. J. Immunol. 1979; 123: 1478–1483
   PubMed Web of Science ®Google Scholar
• Slavin S., Weiss L., Morecki S., Weigensberg M. Eradication of murine leukemia with histocompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol. Immunother. 1981; 11: 155–158
   Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Impact of pre-transplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity and tolerance after bone marrow transplantation. Blood 1991; 77: 2515–2523
   PubMed Web of Science ®Google Scholar
• Sykes M., Pearson D. A. Alloengraftment in IL-2 treated mice. Bone Marrow Transplantation 1992; 10: 157–163
   PubMed Web of Science ®Google Scholar
• Glass B., Uharek L., Gassman W., Focks B., Bolouri H., Loeffler H., Mueller-Ruchholtz W. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. Ann. Hematol. 9912; 64: 255–259
   Google Scholar
• Johnson B. D., Drobyski W. R., Truitt R. L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation 1993; 11: 329–336
   PubMed Web of Science ®Google Scholar
• Drobyski W. R., Keever C. A., Roth M. S., Koethe S., Hanson G., McFadden P., Gottschall J. L., Ash R. C., Van Tuinen P., Horowitz M. M., Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell clone. Blood 1993; 82: 2310–2318
   PubMed Web of Science ®Google Scholar
• Aizawa S., Sado T., Kamisaku H., Nemoto K., Yoshida K. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias. Bone Marrow Transplantation 1994; 13: 109–119
   PubMed Web of Science ®Google Scholar
• Salomo M., Steinmann J., Glass B., Herwartz C., Uharek L., Gassmann W., Muller-Ruchholtz W. Leukemia-specific allogeneic donor T cells: Quantification by limiting dilution assay. Bone Marrow Transplantation 1995; 15: 179–186
   PubMed Web of Science ®Google Scholar
• Faber L. M., Van Luxemberg-Haijs S. A. P., Veenhof W. F. J., Willemze R., Falkenburg J. H. F. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821–2828
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Chemm C. H., Holler E., Ledderose G., Brehn G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., Barrett A. J., Goldman J. M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381
   PubMed Web of Science ®Google Scholar
• Frassoni F., Fagioli F., Sessarego M., Gualaudi F., Van Lint M. T., Lamparelli T., Occhini D., Figari O., Valbonesi M., Bacigalupo A. The effect of donor leukocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp. Hematol. 1992; 20: 712
   Web of Science ®Google Scholar
• Jiang Y. Z., Cullis J. O., Kanfer E. J., Goldman J. M., Barrett A. J. T and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat transfusion to treat relapse after bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplantation 1993; 11: 133–138
   PubMed Web of Science ®Google Scholar
• BÄR B. M., Schattenberg A., Mensink E. J., Geurts Van Kessel A., Smetsers T. F., Knops G. H., Linders E. H., Dewitte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 1993; 11: 513–519
   PubMed Web of Science ®Google Scholar
• Kolb H.-J., Schattenberg A., Goldman J. H., Hertenstein B., Jacobsen N., Acrese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., Van Rhee F., Mittermueller J., De Witte T., Holler E., Ansari H. for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukeima. Graft-versus-leukeima effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050
   PubMed Web of Science ®Google Scholar
• Chen W., Peace B. J., Rovira D. K., You S. G., Cheever M. A. T-cell immunity to the joining region of P210 BCR-ABL protein. Proc. Natl. Acad. Sci. USA 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Chen L. T cell costimulation for cancer immunotherapy. Cancer Chemotherapy Vol. 9, K. Kimura, K. Ota, S. K. Carter, T Friedmann. Exerpta Medica, Tokyo 1994; 85–89
   Google Scholar
• Dranoff G., Jaffee E., Lazenby A., Golumbeck P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. SCi. USA 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar